NAGOYA, Japan, June 30, 2026
Kowa Company, Ltd. has achieved a significant regulatory milestone after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its investigational Selective PPARα Modulator (SPPARMα) K-808 (pemafibrate) for the treatment of Primary Biliary Cholangitis (PBC). The designation recognizes the therapy’s potential to offer a substantial improvement over currently available treatment options for patients living with this rare, chronic autoimmune liver disease. Based on encouraging preliminary findings from the ongoing Phase II K-808-2.01 clinical trial, the FDA’s decision is expected to accelerate the clinical development and regulatory review of the investigational therapy. The breakthrough designation reinforces Kowa’s commitment to expanding treatment options for patients with inadequate response or intolerance to ursodeoxycholic acid (UDCA), the current standard first-line therapy. By advancing K-808, the company aims to address a significant unmet medical need while strengthening its pipeline of innovative therapies targeting serious liver diseases.
Phase II Data Supports FDA Breakthrough Therapy Designation
The FDA granted Breakthrough Therapy Designation after reviewing preliminary clinical evidence from the ongoing Phase II K-808-2.01 trial, which demonstrated encouraging improvements in patients with Primary Biliary Cholangitis. The investigational therapy achieved a significant reduction in alkaline phosphatase (ALP) levels, an important biomarker associated with disease progression and treatment response in PBC. These positive findings were presented earlier this year during the European Association for the Study of the Liver (EASL) Congress 2026, highlighting the potential of pemafibrate to provide clinically meaningful benefits beyond currently available therapies. The FDA’s Breakthrough Therapy program is designed to expedite the development and review of medicines that demonstrate substantial improvement over existing treatments for serious or life-threatening diseases, allowing closer collaboration between regulatory authorities and developers throughout the clinical development process.
K-808 Targets a Rare Autoimmune Liver Disease
Primary Biliary Cholangitis (PBC) is a rare, progressive autoimmune liver disease characterized by chronic inflammation and destruction of the small bile ducts within the liver. As the disease advances, patients may develop fibrosis, cirrhosis, liver failure, and debilitating symptoms including severe fatigue and persistent itching (pruritus) that significantly impact quality of life. PBC predominantly affects women, and while ursodeoxycholic acid (UDCA) remains the standard first-line treatment, many patients either fail to achieve adequate disease control or are unable to tolerate therapy. K-808 is being developed for use in combination with UDCA for patients with an inadequate response or as monotherapy for patients who cannot tolerate UDCA, offering the potential to expand therapeutic options for this underserved patient population. The investigational therapy is based on pemafibrate, a Selective PPARα Modulator (SPPARMα) originally developed by Kowa and currently marketed in Japan as Parmodia® for the treatment of hyperlipidemia.
Advertisement
Global Development Strategy Advances Rare Liver Disease Treatment
Kowa continues advancing the global development of K-808 with the objective of securing regulatory approvals in the United States, Japan, and other international markets. Through activation of the PPARα nuclear receptor, pemafibrate is believed to improve liver function by reducing bile acid synthesis, promoting micellization of hydrophobic bile acids, improving lipid metabolism, and producing anti-inflammatory effects that may slow disease progression. The FDA’s Breakthrough Therapy Designation is expected to accelerate future clinical development, regulatory interactions, and review timelines as Kowa works toward bringing a potentially first-in-class treatment option to patients living with Primary Biliary Cholangitis. As global interest in innovative therapies for rare liver diseases continues to grow, the designation further strengthens Kowa’s position in hepatology research while highlighting the expanding role of precision-targeted therapies in addressing complex autoimmune conditions.
Source: Kowa Company, Ltd press release
